Siemens and Haifu collaborate on high intensity ultrasound tumour
3 March 2006
Siemens Medical Solutions and Chinese company Chongqing Haifu (Haifu)
Technology Co., Ltd. are to collaborate to develop a magnetic resonance
imaging (MRI) guided high-intensity focused ultrasound (HIFU) therapy
The main applications of this system will focus on women's health
treatments including benign uterine fibroids and cancer, as well as
malignant and benign tumors of the liver, kidney, pancreas and bone.
"Combining Siemens' MRI technology with Haifu's unmatched clinical
expertise in non-invasive, fast HIFU protocols will further the ability to
identify and treat tumours, improving care options for doctors and patients
alike," said Nancy Gillen, vice president, MRI Division, Siemens Medical
Solutions. "With innovations such as Tim technology and powerful
applications, Siemens' MRI solutions provide the ideal partner with their
ability to visualize disease states and thus allow for earlier treatment."
The combination of MRI and HIFU enables improved visualization of tumour
morphology and more precise thermal dose control, designed to reduce current
treatment times. Further developments involve MRI applications for
diagnosis, therapy planning and outcome assessment. Patient treatment will
be performed on a special HIFU patient bed inside the bore of Siemens' MRI
scanners. For example, the MAGNETOM EspreeTM with Tim (Total imaging matrix)
technology is well suited for the treatment since it provides the HIFU beam
excellent access to the tumor location as it offers maximum freedom for
patient positioning. Sonication of uterine fibroids is expected to take
considerably less time than with traditional technology.
"We are excited to partner with Siemens Medical Solutions to offer
advanced HIFU technology, improving treatment options to our customers and
the medical industry," said Professor Zhibiao Wang, president, Haifu. "Haifu
has great international success with ultrasound-guided HIFU treatment and we
believe using MRI as a guided imaging modality is the future of this
technology, providing a new direction to advance tumour treatment."